Hepatic Disease

Latest News

The Liver Meeting 2024: Bausch Health Presents Phase 3 Study Design for Investigational Rifaximin Formulation to Delay OHE / Image credit: ©Shidlovski/Shutterstock.com
The Liver Meeting 2024: Bausch Health Presents Phase 3 Study Design for Investigational Rifaximin Formulation to Delay OHE

November 19th 2024

The RED-C clinical trial program highlights the promising potential of the rifaximin soluble solid dispersion immediate-release tablets for delaying early HE-related decompensation.

Semaglutide 2.4 mg: Shows Superior Improvement in Liver Fibrosis, MASH Resolution in Pivotal Phase 3 Trial
Semaglutide 2.4 mg: Shows Superior Improvement in Liver Fibrosis, MASH Resolution in Pivotal Phase 3 Trial

November 4th 2024

Monotherapy with Rifaximin vs Lactulose More Effective for Reducing Recurrence of Overt Hepatic Encephalopathy: New Post Hoc Analysis / image credit: Jasmohan Bajaj, MD, American college of Gastronenterology
Monotherapy with Rifaximin vs Lactulose More Effective for Reducing Recurrence of Overt Hepatic Encephalopathy: New Post Hoc Analysis

October 28th 2024

Survodutide: Novel GCGR/GLP-1RA Shows Promise in Obesity, MASH Treatment
Survodutide: Novel GCGR/GLP-1RA Shows Promise in Obesity, MASH Treatment

September 11th 2024

Tirzepatide Superior to Placebo in MASH Resolution, Fibrosis Improvement: Daily Dose / image credit: ©New Africa/AdobeStock
Tirzepatide Superior to Placebo in MASH Resolution, Fibrosis Improvement: Daily Dose

June 17th 2024

<1234
© 2024 MJH Life Sciences

All rights reserved.